Health Catalyst (NASDAQ:HCAT) Now Covered by Analysts at Goldman Sachs Group

Goldman Sachs Group began coverage on shares of Health Catalyst (NASDAQ:HCAT) in a research note released on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $49.00 target price on the stock.

Several other brokerages have also issued reports on HCAT. Evercore ISI began coverage on Health Catalyst in a research note on Monday. They set an outperform rating and a $50.00 price target for the company. SunTrust Banks began coverage on Health Catalyst in a research note on Monday. They set a buy rating and a $53.00 price target for the company. William Blair began coverage on Health Catalyst in a research note on Monday. They issued an outperform rating for the company. JPMorgan Chase & Co. began coverage on Health Catalyst in a research note on Monday. They issued an overweight rating and a $50.00 target price for the company. Finally, Piper Jaffray Companies began coverage on Health Catalyst in a research note on Monday. They issued an overweight rating and a $47.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, Health Catalyst currently has an average rating of Buy and an average target price of $51.29.

Shares of HCAT stock opened at $42.94 on Monday. Health Catalyst has a 12-month low of $36.29 and a 12-month high of $49.85.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

Featured Story: What is a CD ladder?

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.